Siglec-E Is Up-Regulated and Phosphorylated Following Lipopolysaccharide Stimulation in Order to Limit TLR-Driven Cytokine Production


*J Immunol* 2009; 183:7703-7709; Prepublished online 23 November 2009;
doi: 10.4049/jimmunol.0902780
http://www.jimmunol.org/content/183/12/7703

**Supplementary Material**

http://www.jimmunol.org/content/suppl/2009/11/23/jimmunol.0902780.DC1

**References**

This article cites 34 articles, 13 of which you can access for free at:
http://www.jimmunol.org/content/183/12/7703.full#ref-list-1

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

**Errata**

An erratum has been published regarding this article. Please see next page or:
/content/184/3/1655.full.pdf
Siglec-E Is Up-Regulated and Phosphorylated Following Lipopolysaccharide Stimulation in Order to Limit TLR-Driven Cytokine Production

Caroline R. Boyd,* Selinda J. Orr,2* Shaun Spence,* James F. Burrows,* Joanne Elliott,* Helen P. Carroll,* Kiva Brennan, † Joan Ní Gabhann, ‡ Wilson A. Coulter, † James A. Johnston,3* and Caroline A. Jefferies3†

Although production of cytokines by TLR is essential for viral and bacterial clearance, overproduction can be detrimental, thus controlling these responses is essential. CD33-related sialic acid binding Ig-like lectin receptors (Siglecs) have been implicated in the control of leukocyte responses. In this study, we report that murine Siglec-E is induced by TLRs in a MyD88-specific manner, is tyrosine phosphorylated following LPS stimulation, and negatively regulates TLR responses. Specifically, we demonstrate the Siglec-E expression inhibits TLR-induced NF-κB and more importantly, the induction of the antiviral cytokines IFN-β and RANTES. Siglec-E mediates its inhibitory effects on TLR domain containing adaptor inducing IFN-β (TRIF)-dependent cytokine production via recruitment of the serine/threonine phosphatase SHP2 and subsequent inhibition of TBK1 activity as evidenced by enhanced TBK1 phosphorylation in cells following knockdown of Siglec-E expression. Taken together, our results demonstrate a novel role for Siglec-E in controlling the antiviral response to TLRs and thus helping to maintain a healthy cytokine balance following infection. The Journal of Immunology, 2009, 183: 7703–7709.

O

n facing an immune challenge, the body’s initial response involves activation of the innate immune system. One branch of this uses the pathogen recognition receptors of the TLR family. In mammals, thirteen of these receptors have been identified and they recognize a diverse array of pathogen associated molecular patterns expressed by bacteria, viruses, and fungi (reviewed in Ref. 1). Once engaged, these receptors trigger a signaling cascade that ultimately leads to the activation of transcription factors such as NF-κB and members of the IFN regulatory factor family and thus the production of proinflammatory cytokines (reviewed in Ref. 2).

The production of inflammatory cytokines by these receptors is essential in controlling pathogen replication within the host. However, regulation of the response is essential to prevent pathogenesis. A number of inhibitory mechanisms have been reported to control the activation of the TLRs with the majority targeting the MyD88-dependent arm. These include IL-1 receptor associated kinase-M (3), MyD88s (4), and TRIM30α (5). Increasingly, regulators specific to TIR domain containing adaptor inducing IFN-β (TRIF)-dependent signaling have been identified, for example sterile α- and armadillo-motif containing protein (SARM)6 (6), Ro52 (7), and TRAM adaptor with GOLD domain (8). Recently the phosphatase, PTP1B, has been identified as an inhibitor of both MyD88 and TRIF-dependent responses in macrophages (9).

The importance of negative regulators of pathways that control type I IFN production is highlighted by the role these cytokines play in the pathogenesis of the autoimmune disease systemic lupus erythematosus. Recently, TLR-7 and -9 have been demonstrated to play an important role in the overproduction of type I IFN associated with this disease. To this end, attention is very much focused on uncovering novel mechanisms for regulating TLR-driven IFN production to manipulate these responses therapeutically.

The CD33-related sialic acid binding Ig-like lectins (Siglecs) (CD33 and Siglecs 5–11), are predominantly expressed on cells of the innate immune system and have been largely shown to be inhibitory based on the presence of an ITIM in their cytoplasmic tail. Following ligation of the receptors the tyrosines within the ITIM become phosphorylated and recruit SH2-containing phosphatases such as Src homology 2 domain containing protein tyrosine phosphatase 1 (SHP1) and SHP2, thereby regulating cellular activity (10, 11). More recently, the generation of Siglec knockout mice has further strengthened their importance as inhibitory receptors. Siglec-F-deficient mice displayed enhanced eosinophilic inflammation (12) while Siglec-G-deficient mice had enhanced expansion of B1a cells (13) due to enhanced NF-κB activation (14).

4 Abbreviations used in this paper: SARM, sterile α- and armadillo-motif containing protein; Siglec, sialic acid binding Ig-like lectin; SHP1, Src homology 2 domain containing protein tyrosine phosphatase 1; BMDM, bone marrow-derived macrophage; GAM, goat anti-mouse; TRIF, TIR domain containing adaptor inducing IFN-β; shRNA, short hairpin RNA.

Copyright © 2009 by The American Association of Immunologists, Inc. 0022-1767/09/$2.00

4 Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, U.K.; Molecular and Cellular Therapeutics and RCSI Research Institute, Royal College of Surgeons in Ireland, Dublin, Ireland; and School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, U.K.

Received for publication August 21, 2009. Accepted for publication October 12, 2009.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked ‘advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† Current address: Cancer and Inflammation Program, National Cancer Institute-Frederick, Frederick, MD 21702.

‡ Address correspondence and reprint requests to Jim Johnston, Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast U.K., BT9 7BL, or Caroline Jefferies, Molecular and Cellular Therapeutics and RCSI Research Institute, Royal College of Surgeons in Ireland.

E-mail addresses: jim.johnston@qub.ac.uk and cjjefferies@rcsi.ie

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0902780

Copyright © 2009 by The American Association of Immunologists, Inc. 0022-1767/09/$2.00

4 Abbreviations used in this paper: SARM, sterile α- and armadillo-motif containing protein; Siglec, sialic acid binding Ig-like lectin; SHP1, Src homology 2 domain containing protein tyrosine phosphatase 1; BMDM, bone marrow-derived macrophage; GAM, goat anti-mouse; TRIF, TIR domain containing adaptor inducing IFN-β; shRNA, short hairpin RNA.

Copyright © 2009 by The American Association of Immunologists, Inc. 0022-1767/09/$2.00
To date the myeloid-specific Siglecs, human Siglec-9 and its murine orthologue Siglec-E, have been less well characterized. Recently engagement of Siglec-9 has been shown to result in reduced TNF-α production accompanied with increased IL-10 levels (15). However, involvement of these receptors in pathways leading to type 1 IFN production has not been demonstrated. Siglec-E is expressed mainly on cells of a myeloid lineage (16), although what regulates its expression has not yet been demonstrated. We hypothesized that, given the inhibitory nature of this family of receptors, Siglec-E expression was regulated by TLRs and thus it had a role in modulating the immune response to TLR ligands. In this study, we show Siglec-E is induced in a MyD88-dependent manner and that once up-regulated it can control TLR-dependent NF-κB responses. Furthermore, Siglec-E recruits the negative regulator of TRIF-dependent signaling, SHP2. In keeping with Siglec-E as a negative regulator of TRIF-dependent signaling, overexpression of Siglec-E directly inhibited TLR-induced IFN-β and RANTES reporter gene activation. Notably, short hairpin RNA (shRNA) targeting Siglec-E mRNA enhanced TBK1 phosphorylation and RANTES production thus implicating Siglec-E as a novel negative regulator of TRIF dependent signaling.

Materials and Methods

Cell culture
Bone marrow-derived macrophages (BMDMs) were prepared from C57BL mice and cultured for 1 wk in DMEM supplemented with 10% FCS, 1% pen/strep, and 1% L-glutamine. Proliferation was driven by granulocyte macrophage-CSF derived from L929 supernatent. TLR3- and TLR4-HEK and 293T cells were maintained as described (7). Immortalized BMDMs from wild type, TRIF, and MyD88 knockout mice were cultured in DMEM supplemented with 10% FCS and 1% pen/strep and L-glutamine.

Plasmids and reagents
The Siglec-E plasmid and primary Ab were gifts from Prof. Paul Crocker (University of Dundee, Scotland). TLR-2, -3, and -7 ligands were supplied by InvivoGen, ultrapure Escherichia coli LPS by Alexis Biochemicals, and CpG from Coley Pharmaceuticals.

Immunoprecipitation and Western blotting. Lysates were generated and separated as previously described (17). They were immunoprecipitated with anti-SHP2 (Santa Cruz Biotechnology) or anti-phosphotyrosine (clone 4G10) (Upstate Biotechnology) and pY20 (Zymed). Western blots were probed with anti-Siglec-E or anti-γ-tubulin (Sigma-Aldrich).

Luciferase reporter assays. Luciferase reporter assays were preformed as previously described (7).

Cross-linking Siglec-E. BMDMs were treated with 100 ng/ml LPS for 6 h before cross-linking with α-Siglec-E and goat anti-mouse (GAM) whole molecule (IgG) (Sigma-Aldrich).

RNA interference. A shRNA construct targeting Siglec-E (TCCACAGAGGAAGATACATTATCGAC) or a scrambled shRNA were purchased from OriGene. RAW264.7 or BMDM cells were retrovirally infected with constructs as described previously (18). Infected cells were selected for using 4 μg/ml puromycin (Sigma-Aldrich). Siglec-E mRNA levels were determined using OneStep RT-PCR kit (Qiagen) according to the manufacturer’s instructions. Following LPS stimulation, supernatants were collected and RANTES levels determined by ELISA (R&D Systems) according to the manufacturer’s recommendations.

Statistical analysis
Data shown as means ± SD of triplicates. Statistical significance was determined by one-way ANOVA with a value of p < 0.05 considered statistically significant.

Results

Siglec-E is induced and phosphorylated in a MyD88-dependent manner

The human orthologue of Siglec-E, Siglec-9, has been shown to act as a negative regulator of TLR signaling via the induction of the anti-inflammatory cytokine IL-10 (15). As initial observations demonstrated a low constitutive level of Siglec-E on murine BMDMs, we set out to investigate the ability of TLRs to regulate Siglec-E expression and its ability to inhibit their activity in return. A range of TLR ligands were therefore used to stimulate BMDMs and their ability to drive Siglec-E expression assessed by Western blotting. LPS stimulation of BMDMs was found to drive Siglec-E expression, with increased levels observed at 12 h and Siglec-E strongly expressed at 24 h (Fig. 1A). A similar pattern of induction was observed following stimulation of BMDMs with LPS derived from Porphyromonas gingivalis (TLR2 agonist), CpG (TLR9 agonist), and Imiquimod (TLR7 agonist) indicating that a wide range of TLR agonists can drive Siglec-E expression (Fig. 1, B–D, respectively). In contrast, stimulation of cells with the TLR3 agonist poly(I:C) was consistently unable to induce Siglec-E expression (Fig. 1E). Yet, we observed robust IκB degradation in response to poly(I:C) treatment (results not shown).

Given our findings, we hypothesized that Siglec-E expression may be dependent on differential usage of the adapter molecules MyD88 by the various TLRs; in particular, TLR3 does not signal via MyD88. To investigate this, immortalized BMDMs from TRIF−/− mice or MyD88−/− mice were stimulated with LPS for 24 h. In response to LPS challenge, TRIF−/− BMDMs showed robust up-regulation of Siglec-E expression similar to wild-type BMDMs (Fig. 1F). However, LPS was unable to drive Siglec-E expression to any significant degree in MyD88−/− cells, confirming that Siglec-E is up-regulated by the TLRs in a MyD88-dependent manner. To date, the signaling pathways initiated by Siglec9 remains poorly understood. However, previously reported inhibitory effects of Siglecs have been attributed to their ITIMs, which recruit tyrosine phosphatases following cross-linking (19). Thus, we sought to determine whether the endogenous, TLR-induced Siglec-E was phosphorylated. BMDMs were stimulated with LPS and cell lysates were immunoprecipitated using an anti-phosphotyrosine Ab. Following immunoblotting with Siglec-E, faint phosphorylation of the receptor was detected at 12 h post-LPS stimulation, whereas by 24 h the receptor was strongly phosphorylated (Fig. 1G). The phosphorylation of Siglec-E mirrored the induction of receptor expression, indicating that the receptor maybe rapidly engaged. This is the first time it has been shown that LPS stimulation induces Siglec-E phosphorylation and strongly indicates the up-regulated Siglec-E plays a functionally significant role in the cell.

Siglec-E expression inhibits NF-κB activation

We therefore set out to determine whether Siglec-E had any effect on TLR-driven responses. In keeping with a role for Siglec-E as a negative regulator of NF-κB activity, transient transfection of TLR4- and TLR3-HEK293 cells with increasing concentrations of Siglec-E resulted in a dose-dependent inhibition of both LPS (Fig. 2A) and poly(I:C) (Fig. 2B) driven NF-κB reporter gene activation.

Previous studies in our laboratory have shown (10, 11) that cross-linking Siglec9 family members promotes strong activation. Thus, following induction of Siglec-E expression in BMDMs by treating cells with LPS, Siglec-E was cross-linked with an anti-Siglec-E Ab and GAM secondary Ab to determine the effect of cross-linking Siglec-E on TLR-induced cytokine production. Consistently, we observed that Siglec-E cross-linking resulted in significantly reduced production of the NF-κB-dependent cytokine TNF-α (p < 0.001) in response to LPS as compared with the response observed in cells treated with a secondary Ab only (Fig. 2C). This was also seen when IL-6 production in response to LPS was examined. Again cross-linking Siglec-E resulted in a significant reduction (p < 0.001) in the production of IL-6 when compared with LPS alone or secondary Ab only (Fig.
Together our results strongly suggest that the engagement and activation of Siglec-E following cross-linking can significantly impair LPS-induced NF-κB activation and subsequent TNF-α and IL-6 production.

Siglec-E regulates TRIF-dependent signaling

Although the role of Siglec family members as negative regulators of innate immune responses is well documented, their ability to influence antiviral immunity and the production of type I IFNs has yet to be determined. IFN-β is a key gene activated by both LPS and poly(I:C) in a TRIF-dependent manner (20). Thus, the effect of Siglec-E expression on IFN-β-promoter reporter gene activity was assessed. Importantly Siglec-E inhibited TRIF-driven IFN-β (Fig. 3A) suggesting Siglec-E acts downstream of TLR-3 and −4 in this pathway. In keeping with this, poly(I:C) stimulation of both IFN-β and RANTES reporter gene activation was dose dependently inhibited by overexpression of Siglec-E (Fig. 3, B and C, respectively).

Our results demonstrated that Siglec-E is a novel negative regulator of type I IFN induction downstream of TRIF and suggested that the up-regulation of Siglec-E by TLRs functioned to down-regulate and limit the induction of type I IFNs poststimulation. To investigate this hypothesis, we knocked down endogenous Siglec-E expression in BMDMs cells using a commercially available shRNA against Siglec-E or a scrambled control shRNA and examined its effects on the type I IFN-dependent chemokine RANTES (21). Wild-type cells and cells expressing either scrambled or Siglec-E-specific shRNA were treated with LPS for 6 h and RANTES production examined by ELISA. Enhanced RANTES production was observed in response to LPS in cells in which Siglec-E had been depleted compared with those treated with scrambled shRNA (Fig. 3D). Using one-way ANOVA, this was found to be significant at p < 0.001. Immunoblotting confirmed BMDMs stably transfected with shRNA specific to Siglec-E prevented its up-regulation in response to LPS stimulation while the scrambled shRNA had no effect (Fig. 3D, bottom). To determine whether Siglec-E expression impacted on upstream signal transduction, we examined TBK1 activation. Compellingly, depleting endogenous Siglec-E levels altered TBK1 phosphorylation (Fig. 3E). In RAW 264.7 cells expressing nonspecific shRNA LPS stimulation resulted in the phosphorylation of TBK1 at 60 and 90 min, indicating that TBK1 was activated in response to TLR4 stimulation. In cells which had been “primed” with a 24 h pretreatment of LPS, TBK1 phosphorylation was observed following pretreatment but reduced at 60 and 90 min following restimulation, indicating that TBK1 activity was down-regulated during the course of retreatment of cells with LPS. In contrast, depletion of endogenous Siglec-E resulted in constitutively phosphorylated TBK1 both in the absence of LPS and following LPS treatment, indicative of an inability of cells lacking Siglec-E to regulate TBK1 activity appropriately (Fig. 3E, panel 3, lanes 1–3 and 4–6, respectively). Siglec-E knockdown was confirmed by analyzing mRNA levels of the protein (Fig. 3F).
LPS induced Siglec-E can interact with SHP1 and SHP2

As with other CD33-related Siglecs, Siglec-E has been shown to interact with SHP1 and SHP2 in over-expression systems and using pervanadate pretreatment to maintain proteins in a tyrosine phosphorylated state (22, 23). SHP1 and SHP2 are protein-tyrosine phosphatases that regulates a variety of cellular processes (24, 25) and both have been reported to negatively regulate TLR signaling (26, 27). As Siglec-E was phosphorylated following TLR induction, we sought to examine whether it could recruit endogenous SHP1 and SHP2. Immunoprecipitation of Siglec-E from cells stimulated with LPS for 24 h revealed that up-regulated Siglec-E strongly associated with endogenous SHP1 (Fig. 4A) and SHP2 (Fig. 4B). Thus, this provides a potential mechanism for the observed inhibitory effects on the TLR-signaling pathways.

Siglec-E expression coincides with TLR-induced tolerance

As Siglec-E expression in BMDMs was induced by TLRs, we next examined whether Siglec-E was expressed in a physiologically relevant situation. The kinetics of Siglec-E up-regulation led us to postulate that it may play a role in endotoxin tolerance. Macrophages exhibit maximal tolerance to LPS restimulation at 24 h and this timing coincides with the up-regulation of Siglec-E (as shown in Fig. 1), thus we examined Siglec-E expression levels in various tolerance situations. As readouts of tolerance we examined iκB degradation and MAPK activation in the presence and absence of Siglec-E. To induce Siglec-E the BMDMs were pretreated with the stated ligand for 24 h and restimulated for the times shown. In parallel BMDMs were incubated with growth medium only and these are referred to as naive macrophages. As shown in Fig. 5A phosphorylation of JNK, p38, and ERK was apparent in naive macrophages (lanes 2–6, panels 1, 3, and 5) but strongly suppressed in LPS-tolerant cells (lanes 8–12, panels 1, 3, and 5). The deficient MAPK activation observed in the tolerized macrophages coincided with Siglec-E expression (lanes 6–12, panel 7).

Similarly, pretreating the cells for 24 h with LPS resulted in tolerance to Poly(I:C) stimulation (Fig. 5B). Stimulation with Poly(I:C) caused JNK, p38, and ERK activation in naive BMDMs (lanes 4 and 5, panel 1, 3, and 5) and this was abolished in macrophages pretreated with LPS (lanes 10 and 11, panels 1, 3, and 5). Again Siglec-E expression was clearly up-regulated in these tolerized macrophages (lanes 6–12, panel 7).

Notably, pretreating the cells with poly(I:C) failed to inhibit subsequent LPS induced MAPK activation (Fig. 5C, lanes 2–5, compared with lanes 8–11, panels 1, 3, and 6). In contrast, the phosphorylation of JNK and p38 was extended (lanes 3–6 compared with 9–12, panels 1 and 3). This lack of tolerance coincided with the absence of Siglec-E expression (lanes 6–12, panel 7). However, it is possible that the observed tolerance throughout the experiments is not solely Siglec-E dependent. This pattern was also observed when iκB degradation was examined under the same conditions (supplementary Fig. 1) clearly showing that poly(I:C) pretreatment did not induce LPS tolerance.

Discussion

This study is the first to demonstrate that Siglec-E is induced in a MyD88-dependent manner and is phosphorylated in response to TLR stimulation. Once up-regulated, Siglec-E inhibits NF-κB activation and represses the production of NF-κB dependent cytokines, TNF-α, and IL-6. However, the inhibitory effect of Siglec-E on TLR signaling is not limited to blockade of NF-κB activation.
Significantly, phosphorylated Siglec-E is able to recruit the negative regulator of TBK1, SHP2, to turn off and limit TLR-induced IFN-β induction. Combined, our findings point toward a model in which Siglec-E is induced and subsequently acts in a negative feedback loop to suppress TLR-dependent cytokine and chemokine induction, as evidenced by the ability of Siglec-E to inhibit NF-κB, IFN-β, and RANTES reporter gene activity.

TLR-induced cytokine and chemokine induction is inhibited at multiple levels and by many mechanisms and induction of negative regulators of TLR signaling is a common means of regulating their activity. For example, the TRAIL receptor (28), ST2 (29), and MyD88s (4) are all induced upon stimulation of cells with LPS to feedback and prevent excessive TLR-driven cytokine production. We consistently observed that TLR2, 4, 7, and 9 up-regulated Siglec-E expression whereas poly(I:C) treatment did not. This differential up-regulation could suggest Siglec-E plays a precise role in the TLR signaling cascade, as it is not universally induced by all TLR ligands. This is reminiscent of TRAIL receptors which are differentially up-regulated by TLRs (28). Interestingly this is the not the first example of CD33-related Siglec expression levels being altered in immunopathology. Specifically, Siglec-F is up-regulated on eosinophils and CD4+ T cells during allergic lung inflammation, suggesting that it has a nonredundant role in the negative regulation of atopy (12). Although induction of inhibitory receptors are only one level of control, their importance in regulating inflammatory cytokine production is evidenced by reports that ST2−/− and SIGIRR−/− mice are hyperresponsive to LPS challenge (29, 30). Furthermore, the clinical significance of these inhibitory receptors has recently been highlighted with the findings that SIGIRR prevents the development of murine lupus (31).
data are the first demonstration of expression of a Siglec family member being regulated by TLRs in a MyD88-dependent manner and strongly supports a role for these receptors as being important in innate immune function. In keeping with this, overexpressed Siglec-E inhibits TLR-induced NF-κB activation and furthermore, in a more physiological context, Ab cross-linking, and hence activation of Siglec-E reduces the expression of TNF-α and IL-6 in response to TLR stimulation of cells. Consistent with previous reports showing that Siglec-G and Siglec-9 can negatively regulate NF-κB activation (14) and TLR-induced production of TNF-α (15), respectively.

Our studies show, as demonstrated by previous in vitro overexpression studies (22, 23), that TLR-induced Siglec-E can interact with endogenous SHP1 and SHP2. The effective transmission of the TLR-induced signaling cascade involves, in part, tyrosine phosphorylation of receptors and signaling adaptors. This is exemplified with findings that tyrosine phosphorylation of Mal is essential for it to signal (32) and inhibition of Bruton’s tyrosine kinase results in decreased DNA binding ability of NF-κB in response to LPS treatment (33). Of equal importance is the control of these phosphorylation events, often by the recruitment of phosphatases such as SHP1 and SHP2. Both these proteins have been reported to be involved in negatively regulating the TLR cascade with SHP1 regulating NF-κB (27) and SHP2 regulating the TRIF-dependent signaling cascade (26). As Siglec-E is induced by TLR stimulation and can bind SHP1 and SHP2, we postulated Siglec-E is the mechanism by which these phosphatases get recruited into the signalsome to dampen the response. Because the endogenous signaling network is complex and involves numerous cross-talk pathways, we assume other signals dictate what SHP is recruited to Siglec-E thus dictating whether NF-κB or IFN regulatory factor activation is inhibited. Interestingly, we found knockdown of Siglec-E failed to impact on IκB degradation or TNF-α production (data not shown) even though we demonstrated Siglec-E could inhibit this pathway. Presumably due to the number of known inhibitors of the MyD88 signaling cascade (IL-1 receptor associated kinase-M, ST2, MyD88s), there is a degree of redundancy between these molecules and our results suggest that in the absence of Siglec-E this pathway can still be curtailed. Significantly, TRIF-dependent signaling was affected by the absence of Siglec-E, suggesting that the major function of Siglec-E is to regulate the expression of type 1 IFNs. This could allow the body to respond to a bacterial infection while not producing unnecessary antiviral cytokines. The identification of proteins that inhibit IFN induction is a relatively new field. Like Siglec-E, the TIR domain-containing adaptor SARM has recently been identified as a negative regulator of TRIF-dependent TLR signaling. Similar to our findings, Carty et al. (6) demonstrated that expression of SARM blocked gene induction “downstream” of TRIF and that depletion of endogenous SARM expression by interfering RNA led to enhanced TRIF-dependent cytokine and chemokine induction. However, subsequent studies using SARM deficient mice revealed no defects in the immune response (34).

**FIGURE 4.** Induced Siglec-E interacts with SHP1 and SHP2 resulting in augmented TBK1 phosphorylation. BMDMs were treated with 100 ng/ml LPS for 24 h and lysed in RIPA. Lysates were immunoprecipitated for Siglec-E and immunoblotted for SHP1 (A), SHP2 (B), and Siglec-E. The absence of any nonspecific interaction was determined by using an isotype control Ab.

**FIGURE 5.** MAPK activation is blocked by LPS pretreatment and this coincides with Siglec-E expression. BMDMs were untreated (lanes 1–6) or tolerized with 100 ng/ml LPS (A and B) or 25 μg poly(I:C) (C) for 24 h. Cells were then restimulated with the indicated ligands for the stated times and whole cell lysates were assessed for pJNK, p-p38, and pERK levels. Equal loading was confirmed by immunoblotting for total JNK, ERK, and p38 levels. The data are representative of three independent experiments.
Interestingly, the kinetics of Siglec-E induction is in keeping with other receptors shown to be involved in the development of endotoxin tolerance, including TRL1-R (28) and ST2 (29). Indeed, we find Siglec-E is expressed in BMDMs displaying a tolerant phenotype. This is an area of research that could be pursued with the development of Siglec-E deficient mice.

In conclusion, Siglec-E is induced following LPS stimulation and can subsequently negatively regulate the TLR cascade, thus helping to maintain a healthy cytokine balance following infection. Our findings that Siglec-E also regulates the production of type 1 IFNs downstream of TLRs indicates that this family of receptors may prove to be important therapeutic targets for the treatment of autoimmune diseases such as systemic lupus erythematosus.

Acknowledgments

We thank Prof. Doug Golenbock for the immortalized TRIF−/− and MyD88−/− BMDMs and Michelle de la Vega for helpful discussion.

Disclosures

The authors have no financial conflict of interest.

References


2. The Journal of Immunology 7709


3. The Journal of Immunology 7709


4. The Journal of Immunology 7709


6. The Journal of Immunology 7709


Corrections


Two authors were omitted from the article. The correct author and affiliation lines are shown below.

Caroline R. Boyd,*, Selinda J. Orr,*, Shaun Spence,*, James F. Burrows,*, Joanne Elliott,*, Helen P. Carroll,*, Kiva Brennan,† Joan Ní Gabhann,† Wilson A. Coulter,‡ Claire Jones,‡ Paul R. Crocker,‡ James A. Johnston,* and Caroline A. Jefferies†

*Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, U.K.; †Molecular and Cellular Therapeutics and RCSI Research Institute, Royal College of Surgeons in Ireland, Dublin, Ireland; ‡School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, U.K.; and †The Wellcome Trust Biocentre, School of Life Sciences, University of Dundee, Dundee, U.K.

In addition, the fifth sentence of the Abstract should read “Siglec-E mediates its inhibitory effects on TIR domain containing adaptor inducing IFN-β (TRIF)-dependent cytokine production via recruitment of the tyrosine phosphatase SHP2 and subsequent inhibition of TBK1 activity as evidenced by enhanced TBK1 phosphorylation in cells following knockdown of Siglec-E expression.”

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0990117